18.5 C
Friday, February 3, 2023

Chemotherapy before surgery reduces risk of colon cancer recurrence: study

Health & FitnessChemotherapy before surgery reduces risk of colon cancer recurrence: study

According to the results of A Cancer Research In a UK-funded clinical trial, chemotherapy given to colon cancer patients before surgery reduced the risk of their disease coming back.

The FOxTROT trial showed that giving chemotherapy before chemotherapy after surgery to colon cancer patients reduced the chance of the cancer returning within 2 years by 28%.

A total of 1,053 Colon cancer patients The study, led by scientists from the University of Birmingham and the University of Leeds, involved 85 hospitals in the UK, Denmark and Sweden.

Also read: Salmonella exposure linked to colon cancer: study

Colon cancer patients were divided into two groups in the study. The first group received 6 weeks of chemotherapy, followed by surgery, and then 18 weeks of chemotherapy. The second group had the standard treatment for colon cancer, which was surgery first followed by 24 weeks of chemotherapy.

through Follow-up evaluationsthe scientists found that patients who received chemotherapy before surgery were significantly less likely to have their cancer return, compared to those who received all of their chemotherapy after surgery.

Giving chemotherapy to bowel cancer patients before surgery could be easily adopted by the NHS and other health systems around the world, scientists believe. At least 5,000 colon cancer patients in the UK and millions worldwide could benefit from this treatment every year.

Dr Laura Magill, Associate Professor at the Birmingham Clinical Trials Unit at the University of Birmingham, said:

“1 in 3 colon cancer patients may see their cancer return after surgery. This number is high and we need new treatment strategies to prevent colon cancer from coming back.

“The standard approach is to give chemotherapy after surgery to kill any cancer cells that have spread before surgery. But our research shows that giving some of that chemotherapy before surgery kills all the cancer cells. The chances of getting killed increase.

“A growing body of evidence is showing the value of preoperative chemotherapy in many other cancers, and we believe our findings may change how we approach colon cancer in the clinic.”

In total, 699 patients in the trial received chemotherapy before surgery. Geoff Hoggard, from Leeds, was diagnosed with colon cancer in 2016 and took part in the trial.

“I had seen blood in my poo a few times and was pretty embarrassed about it at first. But eventually I was diagnosed with colon cancer, which was a big wake-up call. The doctors found the cancer very clear with a colonoscopy. I was seen and told that he needed urgent treatment, which came as a huge shock.

“I was willing to take any chance to get the most effective treatment. The FOxTROT trial was the best way to do that, and when my consultant offered to put me on it, I was happy to sign up. .

“I had six weeks of chemotherapy before surgery and 18 weeks after, which was tough. The brain fog and extreme fatigue took its toll on me. Thanks to the support of friends, family and my local church, I kept going. Strength. A permanent source of

“In the end, it was all worth it. I have had no complications since the surgery, and months and years later there are no signs of cancer. 6 years later, I am back to living a full life.

“I have no regrets about participating in the FOxTROT trial. I hope that many others will live long and free of cancer, thanks to the advancing science that will advance this new approach. And that worked very well in my case.”

Professor Matthew Seymour, professor of gastric cancer research at the University of Leeds, said:

“When it comes to treating colon cancer, timing is everything. The simple act of giving chemotherapy, given before rather than after surgery, has yielded some remarkable results.

“Delivering chemotherapy before surgery can prevent cancer recurrence without the need for expensive new drugs or technology. It was particularly encouraging that patients who received chemotherapy before surgery experienced fewer surgical complications. Had to.

“Scrolling this treatment around the world, including in low- and middle-income countries, could transform cancer care and save thousands of lives.”

Scientists are now conducting two more clinical trials, FOXTROT-2 and FOXTROT-3, to investigate whether older patients also benefit from chemotherapy before surgery and to investigate whether more Adding chemotherapy drugs further reduces the chance of the cancer coming back. If these trials are successful, patients may receive more tailored cancer treatments, with new types and combinations of chemotherapy offered to different patients based on how likely they are to benefit from it.

Professor Devon Morton, professor of surgery at the University of Birmingham, said: “Cancer treatments can be prohibitively expensive in many parts of the world. We wanted to go in the opposite direction, testing a treatment that could be used in the widest possible group of people. Can be used on patients.

“Thanks to funding from Cancer Research UK, doctors in countries around the world will now be able to put these findings into clinical practice, saving thousands of lives.”

The paper, titled “Preoperative chemotherapy for operable colon cancer: mature results from an international randomized controlled trial,” was published in the Journal of Clinical Oncology.

This story was published without editing the text from a wire agency feed. Only the title has been changed.


Please enter your comment!
Please enter your name here

Check Out Our Other Content

Check Out Others: